128 related articles for article (PubMed ID: 36408784)
1. Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation.
Zwart TC; Bezstarosti S; Achini FR; Reinders MEJ; Schilham MW; Heidt S; Guchelaar HJ; de Fijter JW; Moes DJAR
Br J Clin Pharmacol; 2023 Apr; 89(4):1471-1485. PubMed ID: 36408784
[TBL] [Abstract][Full Text] [Related]
2. Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation.
van der Zwan M; Baan CC; van Gelder T; Hesselink DA
Clin Pharmacokinet; 2018 Feb; 57(2):191-207. PubMed ID: 28669130
[TBL] [Abstract][Full Text] [Related]
3. Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation.
Dong M; Emoto C; Fukuda T; Arnold DE; Mehta PA; Marsh RA; Vinks AA
Br J Clin Pharmacol; 2022 Jan; 88(1):248-259. PubMed ID: 34182590
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
5. A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients.
Falck P; Midtvedt K; Vân Lê TT; Storehagen L; Holdaas H; Hartmann A; Asberg A
Clin Pharmacokinet; 2009; 48(9):615-23. PubMed ID: 19725595
[TBL] [Abstract][Full Text] [Related]
6. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.
de Winter BC; Monchaud C; Prémaud A; Pison C; Kessler R; Reynaud-Gaubert M; Dromer C; Stern M; Guillemain R; Knoop C; Estenne M; Marquet P; Rousseau A
Clin Pharmacokinet; 2012 Jan; 51(1):29-39. PubMed ID: 22054177
[TBL] [Abstract][Full Text] [Related]
7. Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients.
Guthoff M; Berger K; Althaus K; Mühlbacher T; Bakchoul T; Steurer W; Nadalin S; Königsrainer A; Heyne N
BMC Nephrol; 2020 May; 21(1):178. PubMed ID: 32404066
[TBL] [Abstract][Full Text] [Related]
8. Induction therapy in renal transplant recipients: how convincing is the current evidence?
Wagner SJ; Brennan DC
Drugs; 2012 Mar; 72(5):671-83. PubMed ID: 22439670
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.
Bhoopalan SV; Cross SJ; Panetta JC; Triplett BM
Cancer Chemother Pharmacol; 2020 Dec; 86(6):711-717. PubMed ID: 33037919
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation.
Clatworthy MR; Sivaprakasam R; Butler AJ; Watson CJ
Transplantation; 2007 Dec; 84(12):1563-7. PubMed ID: 18165765
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
Muthusamy AS; Vaidya AC; Sinha S; Roy D; Elker DE; Friend PJ
Am J Transplant; 2008 Oct; 8(10):2126-31. PubMed ID: 18828772
[TBL] [Abstract][Full Text] [Related]
12. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ
Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab for cytolytic induction of immunosuppression in heart transplant recipients.
Cahoon WD; Ensor CR; Shullo MA
Prog Transplant; 2012 Dec; 22(4):344-9; quiz 350. PubMed ID: 23187050
[TBL] [Abstract][Full Text] [Related]
14. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of mycophenolic acid in renal transplant recipients.
van Hest RM; van Gelder T; Vulto AG; Mathot RA
Clin Pharmacokinet; 2005; 44(10):1083-96. PubMed ID: 16176120
[TBL] [Abstract][Full Text] [Related]
18. Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction.
Weissenbacher A; Hautz T; Kimelman M; Oberhuber R; Ulmer H; Bösmüller C; Maglione M; Schneeberger S
J Immunol Res; 2015; 2015():985460. PubMed ID: 26171403
[TBL] [Abstract][Full Text] [Related]
19. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation.
Uemura T; Ramprasad V; Matsushima K; Shike H; Valania T; Kwon O; Ghahramani N; Shah R; Farooq U; Khan A; Kadry Z
Transplantation; 2011 Sep; 92(6):678-85. PubMed ID: 21841541
[TBL] [Abstract][Full Text] [Related]
20. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
Trzonkowski P; Zilvetti M; Chapman S; Wieckiewicz J; Sutherland A; Friend P; Wood KJ
Am J Transplant; 2008 Feb; 8(2):338-47. PubMed ID: 18211507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
